Related Experiment Video
Updated: Dec 13, 2025

In Vitro Selection of Engineered Transcriptional Repressors for Targeted Epigenetic Silencing
Published on: May 5, 2023
The transcriptional repressor REV-ERB as a novel target for disease
Amaia Uriz-Huarte1, Amrita Date1, Heather Ang2
1Department of Chemistry, Imperial College London, Molecular Sciences Research Hub, White City Campus, Wood Lane, London W12 0BZ, UK.
Abstract:
REV-ERB is a member of the nuclear receptor superfamily of transcription factors involved in the regulation of many physiological processes, from circadian rhythm, to immune function and metabolism. Accordingly, REV-ERB has been considered as a promising, but difficult drug target for the treatment of numerous diseases. Here, we concisely review current understanding of the function of REV-ERB, modulation by endogenous factors and synthetic ligands, and the involvement of REV-ERB in select human diseases. Particular focus is placed on the medicinal chemistry of synthetic REV-ERB ligands, which demonstrates the need for higher quality ligands to aid in robust validation of this exciting target.
Insights
Nuclear receptor REV-ERB regulates key physiological processes and is a potential drug target. Developing higher quality synthetic ligands is crucial for validating REV-ERB
Area of Science:
- Molecular biology
- Pharmacology
- Endocrinology
Background:
- REV-ERB, a nuclear receptor, influences circadian rhythms, immunity, and metabolism.
- It presents a promising yet challenging target for therapeutic intervention in various diseases.
Purpose of the Study:
- To review the function and regulation of REV-ERB.
- To explore its role in human diseases.
- To highlight the medicinal chemistry of synthetic REV-ERB ligands.
Main Methods:
- Literature review of REV-ERB function, modulation, and disease involvement.
- Focus on synthetic ligand medicinal chemistry and development.
Main Results:
- REV-ERB's broad physiological roles are established.
- Synthetic ligands show potential but require improvement.
- Higher quality ligands are needed for target validation.
Conclusions:
- REV-ERB is a significant target for drug development.
- Advancements in synthetic ligand chemistry are essential for therapeutic success.
- Further research is needed to fully exploit REV-ERB's potential.
More Related Videos
Related Concept Videos
Master Transcription Regulators
Master Transcription Regulators
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
RNA Polymerase II Accessory Proteins
Co-activators and Co-repressors
Transducer Mechanism: Nuclear Receptors
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:

